New Members

CHI is pleased to welcome new member, ProteoGenix, Inc.


CHI is pleased to welcome new member ProteoGenix, which is focused on the development and commercialization of proprietary products and services for maternal-fetal healthcare.  The foundation for this proprierary technology was created through an integration of genomic, proteomic and bioinformatics research resulting in the identification of diagnostic protein biomarkers for pregnancy-related complications.


Don Mooney, Chief Executive Officer
Don Mooney joined ProteoGenix as president and CEO in 2007.  Prior to joining he served as vice president and CEO for Focus Diagnostics, Inc., an infectious disease company with both laboratory services and global diagnostics products.  Mooney has helped engineer the acquision of Focus by Quest Diagnostics in July 2006.  He has held positions as president of B&L Surgical Group; vice president of commercial operations, Ortho Clinical Diagnostics, a J&J company; and vice president of marketing operations at Ciba Corning/Chiron Diagnostics.  Mooney has been responsible for the success of many medical device platforms.


Robert DiTullio, Vice President of Regulatory Affairs and Quality 
Robert M. DiTullio, Ph.D., joined ProteoGenix as vice president of regulatory affairs and quality in July 2008.  DiTullio has more than 30 years experience in the IVD industry.  He has held positions as vice president of regulatory affairs and quality and clinical affairs for Sequenom and vice president of global regulatory affairs at Siemens Medical Solutions Diagnostics.  Robert is currently the co-chair of the AdvaMed Diagnostics Task Force, was an advisory board member for the medical device graduate degree curriculum at the University of Southern California for several years and has numerous professional regulatory affairs society affiliations.